Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER-B (Aus): Better treatments for refractory breathlessness
ISRCTN15751764Phase 3Completed
- Sponsor
- University of Technology Sydney
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Chronic breathlessness syndrome, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) comparing Mirtazapine with Placebo (2 arms). Primary endpoint: Worst breathlessness over the last 24 hours at day 56. Started May 2021; status: completed.
02
Drugs
mirtazapine
03
Conditions
Chronic breathlessness syndromechronic obstructive pulmonary disease (COPD)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ISRCTN15751764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15751764.